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Late Vascular Response
Following Drug-Eluting
Stent Implantation*
Lorenz Räber, MD,†‡ Patrick W. Serruys, MD, PHD‡
Bern, Switzerland; and Rotterdam, the Netherlands
The therapeutic effect of drug-eluting stents (DES) as
compared with bare-metal stents (BMS) is most pro-
nounced during the first year as a result of the potent
inhibition of neointimal hyperplasia in the presence of
the antiproliferative drug. Whereas healing with BMS,
and in parallel, neointimal proliferation, has been shown
to be complete after 3 to 6 months (1), potentially
followed by a late lumen enlargement beyond 1 year, a
different pattern emerged with early generation DES,
characterized by delayed healing with an ongoing neoin-
timal growth beyond 6 months in both experimental and
clinical studies (2,3). However, the long-term course of
neointimal growth has not been well investigated in early
generation DES, and it remains unclear whether newer
generation DES show a similar response despite im-
provements in design.
See page 1067
In this issue of JACC: Cardiovascular Interventions,
ollet et al. (4) report long-term intravascular ultrasound
IVUS) data from patients included in the first-in-man
valuation of sirolimus-eluting stent (SES) slow-release
ohort and the first-in-man evaluation of biolimus-
luting stent using a biodegradable polymer (BES). All
atients underwent serial IVUS investigation post-
rocedure, between 6 and 12 months and at 4 to 5 years.
eointimal growth was not halted after the first
ollow-up at 6 (BES) and 12 months (SES), respectively,
ut continued to increase with a similar magnitude for
oth BES and SES during long-term follow-up. These
esults indicate that neointimal growth continues with
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polymer-based DES beyond the time point, at which
healing is complete with BMS.
The different time point at which the first follow-up was
performed (6 months in BES vs. 12 months in SES) makes
any comparison of the dynamics in neointimal response
between the 2 stent types questionable. SES release 80% of
the drug during the first 30 days, with nearly all drug eluted
at 3 months, whereas BES is characterized by a bioabsorb-
able abluminal polymer, namely polylactide, which is pre-
dictably degraded by surface hydrolysis to lactide during a
period of 6 to 12 months (5). It remains uncertain whether
the increase in neointimal tissue from 6 months to 5 years
observed with BES is solely related to the decrease of drug
dose, or whether it reflects a true increase beyond 1 year as
the result of impaired healing as has been described in early
generation DES. Since the bioabsorption of the polymer has
been correlated with a transient inflammatory response, it
would be interesting to evaluate the intimal thickness after
completion of biodegradation (12 to 18 months) and during
long-term follow-up (4 to 5 years). Only this design would
allow the investigation of whether BES is associated with an
increasing neointimal proliferation during long-term
follow-up after completion of the bioabsorption process.
BMS Versus Early-Generation DES
In BMS, longitudinal angiographic and angioscopic
follow-up series observed late improvements in lumen
diameter, suggesting fibrotic maturation and regression of
the neointima, and a similar pattern with absence of delayed
late loss beyond 8 months was noted with a polymer-free
DES (6–8). Caution, however, should be exercised because
limited data are available with BMS beyond 3 years. An
optical coherence tomography study reported on a transfor-
mation of the neointima into lipid-laden tissue, reflecting
atherosclerotic progression (9) and very late erosion of the
minimal lumen diameter between 4 and 10 years and
beyond 10 years have been observed in a small angiographic
study. In contrast to BMS, angiographic and IVUS studies
of early generation DES documented a continued increase
in neointimal formation. Recently, the 5-year angiographic
follow-up results of the SIRTAX LATE (Sirolimus-
Eluting versus Paclitaxel-Eluting Stents for Coronary
Revascularization-Late) trial have shown a catch-up of 0.33
 0.66 in delayed late loss between 8 months and 5 years for
both SES and paclitaxel-eluting stents (PES). The study of
Collet et al. (4), not only is confirmatory, but further
improves our understanding in terms of late stent vessel wall
interactions using IVUS. A limitation of this study is that
patients presenting for repeat revascularization of the target
lesion did not undergo IVUS and are not part of the present
analysis. This inherently leads to a much lower absolute
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1076increase in neointimal tissue growth than observed in
reality.
Mechanisms of Late Intimal Growth
in Early-Generation DES
What are the mechanisms responsible for the ongoing
growth of neointima, and how might these be mitigated,
and perhaps most important, are these observations clini-
cally relevant (Fig. 1)? As a first mechanism, the antipro-
liferative drug concentration diminishes over time according
to the individual elution profile of the devices, and with
decreasing dose, the inhibiting effect declines. As a second
mechanism, the presence of fibrin—which has been de-
scribed in the vicinity of stent struts in experimental and
autopsy studies—is an initiator of smooth muscle cell
migration and proliferation (10). Porcine coronary models
have revealed an increasing amount of fibrin in the long-
term course (90 days) following implantation of early
generation DES, and in analogy to prolonged wound
healing that may result in an exaggerated scar formation,
delayed fibrinolysis is a stimulus to smooth muscle cell
proliferation and excessive collagenous matrix formation
(11). Third, chronic inflammation is a trigger for late
neointimal growth, and histological animal studies suggest
that the inflammatory response among different DES ap-
Figure 1. The Different Time Course of the Neointimal Growth (Indicated b
Throughout 5 Years
Different mechanisms contributing to the late neointimal growth in drug-eluti
tima. D and E  D and E domains of ﬁbrinogen. Schematic drawing of ﬁbrino
strut inﬂammatory cell inﬁltrates. In addition, a case example of a sirolimus-elu
Juan Luis Gutiérrez Chico, MD, Vigo, Spain).pears clearly distinct in terms of the proportion of giant
cells, granulomas, eosinophils, lymphocytes, and fibrin de-
position (11). Whereas SES may cause a granulomatous and
eosinophilic reaction starting at 28 days that continues to
increase over time, PES is characterized by lower levels of
inflammation, but higher amounts of fibrin deposition (2).
Information about newer generation DES, such as BES, is
currently still lacking. Fourth, the formation of neoathero-
sclerosis, mainly characterized by in-stent thin-cap
fibroatheroma-containing neointima and neocalcifications,
may reflect a contributing factor that arises later in the time
course and is not yet sufficiently described (12,13).
Clinical Significance of Late Catch-Up
The most relevant question emerging from the observation
by Collet et al. (4) is whether the late “catch up” translates
into a clinically meaningful need for target lesion revascu-
larization (TLR) during long-term follow-up, reducing the
early efficacy benefit of DES. Long-term results from
randomized controlled trials of early and newer generation
DES consistently show a yearly TLR rate of 2% beyond 1
year without any differences as compared with BMS (Table 1).
After subtraction of stent thrombosis–related TLRs (as they
are often not restenosis related), the annual TLR rate is as
low as 1% to 1.5%. Against this background, it is reasonable
Loss) for BMS and for Early- and Newer-Generation DES Is Shown
nts (DES) are presented. SMC M  smooth muscle cell migration into neoin-
referring to Naito et al. (10). Arrow in histological cross section depicts peri-
tent showing delayed neointimal growth is depicted (kindly provided byy Late
ng ste
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1077to conclude that early generation DES delay intimal forma-
tion and healing during the long-term course, yet without
significantly compromising the early benefit in efficacy.
Prolonged neointimal proliferation, however, may be a
useful marker to assess the delay in healing. Of note, delayed
healing has been characterized histologically by lack of
endothelialization and persistent fibrin deposition, and both
were identified as the principal pathological finding in an
autopsy study distinguishing late thrombosed from patent
early generation DES.
Glimpse Into the Future
Newer generation DES were designed to overcome the
limitations of early generation DES. The biocompatibility
of the durable polymers was improved, and the concept of
completely bioabsorbable polymers was introduced. The
strut thickness was further reduced, the drug dose was
adapted, and the release kinetics optimized. Animal studies
revealed a lower rate of uncoverage (marker of healing), and
similar observations were observed using optical coherence
tomography in vivo with both BES and everolimus-eluting
stents as compared with SES (14,15). As these findings
were paralleled by improved clinical outcomes (16), it is
tempting to hypothesize that newer generation DES will
translate into a less pronounced neointimal growth beyond
Table 1. Target Lesion and Stent Thrombosis Rates Beyond 1 Year in BMS
Trial Acronym Stent Type (n) Clinical Setting
Follow-Up
Period
(yrs)
TLR Up to
Maximal Follow
(%)
Early-generation DES (RCTs with 5-yr follow-up)
RAVEL SES (n  120) vs.
BMS (n  118)
Stable CAD 5 10.3 vs. 26.0, p
SIRIUS SES (n  533) vs.
BMS (n  525)
Stable CAD 5 9.4 vs. 24.2, p
TAXUS IV–SR PES (n  651) vs.
BMS (n  643)
Stable and
unstable CAD
5 16.4 vs. 4.3, p 0
SIRTAX LATE SES (n  503) vs.
PES (n  509)
All comers 5 13.1 vs. 15.1, p
Newer-generation DES (RCTs with at least 3 yrs of follow-up)
LEADERS BES (n  857) vs.
SES (n  850)
All comers 3 7.6 vs. 8.8, p 0
ENDEAVOR
pooled
program
ZES (n  2,132) Stable and
unstable CAD
3 6.7
SPIRIT II, III
pooled
EES (n  892) vs.
PES (n  410)
Stable and
unstable CAD
3 5.4 vs. 9.1
TLR is ischemia-driven, if available. *Unpublished data thatwere calculated using outcomes at 1 year
9 months and 5 years. ‡ARC definite or probable stent thrombosis,
ARC Academic Research Consortium; BES biolimus-eluting stent(s); BMS bare-metal stent
Drug-Eluting Coronary Stent System; LEADERS Limus Eluted FromaDurable versus Erodible Stent
With a Standard Stent for Coaronary Revascularization; RCT randomized controlled trial; SES siro
Sirolimus versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial; SPIRIT A Clinic
De Novo Native Coronary Artery Lesions; TAXUS IV-SR Treatment of De Novo Coronary Disease U
stent thrombosis; ZES zotarolimus-eluting stent(s).1 year as a result of less fibrin deposition and less inflam-mation in nonrandomized studies, and, therefore, may
result in less very late stent thrombosis during long-term
follow-up. A common limitation of both early and newer
generation DES is the presence of a permanent metallic
scaffold that serves as the nidus for late adverse stent vessel
wall interactions. Recently, the use of fully bioabsorbable
everolimus-eluting scaffolds have demonstrated their poten-
tial ability to treat coronary artery stenoses, and other fully
absorbable technologies are currently under investigation
(17). Whether these “new kids on the block” will overcome
the aforementioned limitations of conventional metallic
DES has yet to be shown.
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